Sr. No.	Received from	Pending at the end of last month	Received	Resolved*	Total Pending #	Pending complaints >3months	Average Resolution time^ (in days)
1	Directly from Investors	0	0	0	0	0	0
2	SEBI (SCORES)	0	0	0	0	0	0
3	Other Sources (if any)	0	0	0	0	0	0
	Grand Total	0	0	0	0	0	0

Sr. No.

Received from

Pending at the end of last month

Received

Resolved*

Total Pending #

Pending complaints >3months

Average Resolution time^ (in days)

Directly from Investors

SEBI (SCORES)

Other Sources (if any)

Grand Total

Sr. No.	Month	Carried forward from previous month	Received	Resolved*	Pending#
1	Jun, 2026	0	0	0	0
2	Jul, 2026	0	0	0	0
3	Aug, 2026	0	0	0	0
	Grand Total	0	0	0	0

Sr. No.

Month

Carried forward from previous month

Received

Resolved*

Pending#

Jun, 2026

Jul, 2026

Aug, 2026

Grand Total

Sr. No.	Fin. Year	Received	Resolved*
1	2022-23	1	1
2	2023-24	0	0
3	2024-25	0	0
4	2025-26	1	1
	Grand Total	2	2

Sr. No.

Fin. Year

Carried forward from previous year

Received

Resolved*

Pending#

2022-23

2023-24

2024-25

2025-26

Grand Total

Top Pharma Companies in India by Market Cap

BSE Sensex 75397.74 938.21 (1.26%)

Filter

Top Pharma Companies in India as on Nov-2026 | 5 Star Rated Stocks Undervalued Stocks Fair Valued Stocks Uptrend Stocks

Filter

Expand company details	Company Name	DeciZen	Market cap (Rs. Cr.)	CMP (Change %)	Latest P/E	Latest P/BV	5Y Sales Gr.(%)	5Y Profit Gr.(%)	More company information
61	Supriya Lifescience Ltd.	Q V+ PT	6,810 Small Cap	848.25 (0.24%)	N/A	N/A	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
62	Granules India Ltd.	Q V+ PT	22,901 Small Cap	836.65 (-0.35%)	56.84	5.58	2.07	-5.88	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
63	Anthem Biosciences Ltd.	Q V PT	46,685 Mid Cap	826.60 (-0.22%)	81.06	14.92	14.00	16.46	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
64	Orchid Pharma Ltd.	Q V PT	4,989 Small Cap	825.60 (-0.89%)	575.67	3.18	22.33	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
65	Alembic Pharmaceuticals Ltd.	Q V+ PT	15,682 Small Cap	803.30 (0.69%)	22.61	2.68	6.37	-8.79	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
66	Natco Pharma Ltd.	Q V+ PT	15,350 Small Cap	785.65 (0.40%)	13.41	1.45	14.72	28.08	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
67	Fortis Healthcare Ltd.	Q V+ PT	58,117 Mid Cap	763.55 (-0.81%)	55.46	5.72	17.76	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
68	Akums Drugs & Pharmaceuticals Ltd.	Q V PT	11,520 Small Cap	729.95 (-0.27%)	39.49	3.37	9.87	8.26	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
69	Krishna Institute of Medical Sciences Ltd	Q V PT	29,480 Small Cap	712.10 (1.45%)	144.3	7.79	24.04	3.67	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
70	Aster DM Quality Care Ltd.	Q V+ PT	59,570 Mid Cap	687.70 (0.63%)	186.93	14.08	-11.61	19.15	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
71	Manipal Health Enterprises Ltd.	Q V+ PT	87,926 Mid Cap	640.05 (-4.25%)	98.54	5.3	41.64	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
72	Bliss GVS Pharma Ltd.	Q V+ PT	6,898 Small Cap	631 (-2.68%)	42.79	5.34	9.94	8.65	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
73	Indegene Ltd.	Q V+ PT	14,164 Small Cap	628.45 (6.94%)	34.45	4.22	29.44	13.80	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
74	Solara Active Pharma Sciences Ltd.	Q V PT	3,055 Small Cap	627.60 (-0.86%)	82.7	2.13	-3.27	-145.29	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
75	Nephrocare Health Services Ltd.	Q V PT	6,194 Small Cap	611.90 (-0.66%)	80.61	5.46	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
76	Healthcare Global Enterprises Ltd.	Q V+ PT	8,731 Small Cap	586.85 (0.35%)	522.51	5.42	17.43	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
77	Metropolis Healthcare Ltd.	Q V PT	11,310 Small Cap	548.70 (0.65%)	56.09	7.25	10.52	0.55	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
78	Sai Parenterals Ltd.	Q V PT	2,302 Small Cap	513.95 (-1.35%)	139.47	2.95	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
79	Dr. Agarwals Health Care Ltd.	Q V PT	16,117 Small Cap	512.45 (0.81%)	108.63	7.79	34.58	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
80	Lincoln Pharmaceuticals Ltd.	Q V PT	1,005 Small Cap	505.65 (0.74%)	10.38	1.24	9.61	3.24	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
81	Krsnaa Diagnostics Ltd.	Q V+ PT	1,635 Small Cap	504.40 (0.06%)	16.78	1.65	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
82	SMS Pharmaceuticals Ltd.	Q V+ PT	4,793 Small Cap	500.85 (-2.13%)	46.8	5.95	9.51	7.36	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
83	Blue Jet Healthcare Ltd.	Q V PT	9,547 Small Cap	500.05 (-0.86%)	40.64	4.27	13.68	9.45	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
84	Amrutanjan Health Care Ltd.	Q V+ PT	1,436 Small Cap	498 (0.23%)	26.61	3.83	8.59	1.17	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
85	Unichem Laboratories Ltd.	Q V PT	3,404 Small Cap	493.95 (2.17%)	11.17	1.24	12.26	24.44	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
86	Vimta Labs Ltd.	Q V+ PT	2,167 Small Cap	488.80 (0.81%)	26.97	4.41	14.27	28.52	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
87	One Global Service Provider Ltd.	Q V+ PT	854 Small Cap	461 (5.46%)	N/A	N/A	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
88	Thyrocare Technologies Ltd.	Q V PT	7,274 Small Cap	457.45 (0.10%)	50.44	13.14	10.88	8.62	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
89	Aarti Drugs Ltd.	Q V PT	3,977 Small Cap	448.65 (2.97%)	20.8	2.49	3.55	-6.47	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
90	Cohance Lifesciences Ltd.	Q V+ PT	17,005 Small Cap	447.60 (0.71%)	160.07	4.42	17.57	-18.37	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
Prev 1 2 3 4 5 Next

Screens:

AlphaCases Top Rated Stocks Best Nifty Stocks Best Nifty Next Stocks Best Nifty 500 Stocks Best SmallCap Stocks Top BFSI Stocks

Pharma - Today's Top Gainers

Company Name	CMP	Price Change(%)
Indegene	628.45	6.94%
Advanced Enzyme Tech	280.15	6.54%
One Global Service	461	5.46%
Evonile Pharma	1,778.15	4.98%
Rubicon Research	1,682	4.48%

Pharma - Today's Top Losers

Company Name	CMP	Price Change(%)
Morepen Laboratories	108.05	-4.97%
Concord Biotech	1,187.70	-4.63%
Manipal Health Enter	640.05	-4.25%
Strides Pharma Scien	1,031.65	-3.51%
Sigachi Industries	25.50	-3.41%

News about Top Pharma Companies in India

Oct, 2026

Indegene informs about newspaper advertisement

Pursuant to Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Indegene has informed that it enclosed copies of the newspaper advertisement published in Financial Express (English) and Vishwavani (Kannada) today, relating to financial results for 2nd quarter and half year ended September 30, 2026. The above information will be made available on the website of the Company: https://www.indegene.com/.

The above information is a part of company’s filings submitted to BSE.

Oct, 2026

Alembic Pharmaceuticals gets USFDA’s final nod for Venetoclax Tablets

Alembic has a cumulative total of 248 ANDA approvals from the USFDA

Oct, 2026

Manipal Health Enterprises informs about disclosure

Manipal Health Enterprises has informed that it enclosed Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011 on October 30, 2026 for MEMG International India.

The above information is a part of company’s filings submitted to BSE.

Oct, 2026

USFDA completes CGMP inspection at Granules India’s Gagillapur facility

The inspection was conducted from October 19, 2026 to October 30, 2026

Oct, 2026

Vimta Labs - Quaterly Results

A fair growth of 9.95% in the revenue at Rs. 1119.83 millions was reported in the September 2026 quarter as compared to Rs. 1018.48 millions during year-ago period.A meek growth of 3.48% was reported for the quarter ended September 2026 to Rs. 206.14 millions from Rs. 199.20 millions.Operating profit surged to 407.78 millions from the corresponding previous quarter of 368.88 millions.

(Rs. in Million)

	Quarter ended			Year to Date			Year ended
	202609	202509	% Var	202609	202509	% Var	202603	202503	% Var
Sales	1119.83	1018.48	9.95	2210.57	1994.12	10.85	4072.90	3439.82	18.40
Other Income	29.04	26.58	9.26	67.16	44.07	52.39	89.89	42.40	112.00
PBIDT	407.78	368.88	10.55	819.01	723.27	13.24	1505.08	1261.89	19.27
Interest	3.85	3.74	2.94	6.22	6.89	-9.72	11.67	19.00	-38.58
PBDT	403.93	365.14	10.62	812.79	716.38	13.46	1477.25	1242.89	18.86
Depreciation	128.68	102.40	25.66	254.16	201.02	26.44	437.72	352.89	24.04
PBT	275.25	262.74	4.76	558.63	515.36	8.40	1039.53	890.00	16.80
TAX	69.11	63.54	8.77	142.07	127.22	11.67	264.41	222.45	18.86
Deferred Tax	1.58	-3.17	-149.84	16.02	-7.23	-321.58	-1.07	12.66	-108.45
PAT	206.14	199.20	3.48	416.56	388.14	7.32	775.12	667.55	16.11
Equity	89.40	89.08	0.36	89.40	89.08	0.36	89.34	44.47	100.90
PBIDTM(%)	36.41	36.22	0.54	37.05	36.27	2.15	36.95	36.68	0.73

Oct, 2026

Vimta Labs informs about unaudited financial results

Vimta Labs has enclosed unaudited Financial Results as per Regulation 33 of the SEBI (LODR) Regulations, 2015 for the 02nd Quarter and Half Year ended 30th September 2026 along with Limited Review Report. The said Financial Results were duly reviewed and recommended by the Audit Committee and approved by the Board of Directors of the Company, at their respective meetings held today. Further to earlier intimation dated 6th May 2026 regarding the proposed incorporation of a wholly owned subsidiary in the USA, the Board of Directors of the Company, at its meeting held today, took note of the incorporation of Vimta Labs LLC as a wholly owned subsidiary of the Company. The meeting of the Board of Directors of the Company commenced at 10:30 AM and concluded at 01:00 PM.

The above information is a part of company’s filings submitted to BSE.

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Rank	Company	Market Capitalization 2026 (INR crores)
1	Abbott India Ltd.	54,384 Crore
2	Neuland Laboratories Ltd.	25,276 Crore
3	Divis Laboratories Ltd.	2,57,903 Crore
4	Apollo Hospitals Enterprise Ltd.	1,20,779 Crore
5	Astrazeneca Pharma India Ltd.	15,918 Crore
6	Kovai Medical Center & Hospital Ltd.	6,356 Crore
7	Procter & Gamble Health Ltd.	9,436 Crore
8	Dr Agarwals Eye Hospital Ltd.	2,552 Crore
9	Alkem Laboratories Ltd.	61,277 Crore
10	Torrent Pharmaceuticals Ltd.	1,76,306 Crore

Do you know? Asking 3 Right Questions minimizes the RISK of Stock Investing To Know

Right Stock | Right Price | Right Allocation

Find best stocks to buy now Find best pharma stocks to buy now

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

You can use different criterias to arrive at the list of best stocks in the Nifty Pharma company index. You can use return ratios like ROCE or ROE, that will help you choose companies with profitable growth.

Based on ROE, the best stocks in the Nifty Pharma companies index are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	ROE
Abbott India Ltd. (M)	Very Good	25,802	54,384	33.68	10.51	23.07	34.24
Torrent Pharmaceuticals Ltd. (L)	Very Good	4,595	1,76,306	83.01	9.60	33.08	29.04
Glenmark Pharmaceuticals Ltd. (M)	Very Good	2,382	65,137	36.23	5.94	12.08	27.89
Lupin Ltd. (M)	Somewhat Good	2,014	91,870	16.62	3.86	9.20	26.43
Ajanta Pharma Ltd. (M)	Very Good	3,430	43,891	34.76	9.03	23.33	25.35

Based on the past year's gain, the best performing stocks are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	Yearly gain (%)
Laurus Labs Ltd. (M)	Very Good	2,375	1,29,243	147
Sai Life Sciences Ltd. (S)	Somewhat Good	1,565	33,139	69.37
Gland Pharma Ltd. (M)	Very Good	3,090	51,112	61.94
Aurobindo Pharma Ltd. (M)	Very Good	1,665	96,537	52.18
Ipca Laboratories Ltd. (M)	Very Good	1,952	48,907	49.58
				View More

Stocks with the highest revenue growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Sales Growth (%)
Sai Life Sciences Ltd. (S)	Somewhat Good	1,565	33,139	91.61	12.98	47.25	23.61
Mankind Pharma Ltd. (M)	Very Good	2,505	1,02,797	45.84	5.85	24.28	18.10
Ajanta Pharma Ltd. (M)	Very Good	3,430	43,891	34.76	9.03	23.33	13.54
Zydus Lifesciences Ltd. (M)	Very Good	1,250	1,24,089	27.50	4.60	15.32	13.52
Gland Pharma Ltd. (M)	Very Good	3,090	51,112	45.28	4.81	23.17	13.18

Stocks with high profit growth often witness their stock prices gaining, irrespective of the market movements.

Stocks with the highest profit growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Profit Growth (%)
Sai Life Sciences Ltd. (S)	Somewhat Good	1,565	33,139	91.61	12.98	47.25	39.96
Lupin Ltd. (M)	Somewhat Good	2,014	91,870	16.62	3.86	9.20	32.37
Glenmark Pharmaceuticals Ltd. (M)	Very Good	2,382	65,137	36.23	5.94	12.08	22.19
Abbott India Ltd. (M)	Very Good	25,802	54,384	33.68	10.51	23.07	17.33
Dr. Reddys Laboratories Ltd. (M)	Very Good	1,356	1,12,699	40.25	2.90	18.79	15.75

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045

Compliance Officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com	Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com	Telephone: +919860919463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com	Telephone: +919175899463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Current Complaints

*Inclusive of complaints of previous months resolved in the current month. #Inclusive of complaints pending as on the last day of the month.

*Inclusive of complaints of previous months resolved in the current month. #Inclusive of complaints pending as on the last day of the year.

Top Pharma Companies in India by Market Cap

News about Top Pharma Companies in India

Indegene informs about newspaper advertisement

Alembic Pharmaceuticals gets USFDA’s final nod for Venetoclax Tablets

Manipal Health Enterprises informs about disclosure

USFDA completes CGMP inspection at Granules India’s Gagillapur facility

Vimta Labs - Quaterly Results

Vimta Labs informs about unaudited financial results

Publicly traded pharmaceuticals

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

How to select the top Nifty Pharma stocks based on RoE?

What are the best-performing stocks in the Nifty Pharma index?

Which Nifty Pharma stocks have the highest revenue growth in the past five years?

Which Nifty Pharma stocks had the highest profit growth in the past five years ?